Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Oct 9th, 4:27 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | N/A - N/A |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people ( https://ibn.fm/ANk8X ). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options. Addressing this gap, Soligenix (NASDAQ: SNGX) recently announced the expansion of its European Medical Advisory Board (“MAB”) ( https://ibn.fm/6354Y ) to provide additional clinical and strategic guidance as the company advances its confirmatory phase 3 study (referred to as FLASH2) evaluating the safety and efficacy of its proprietary CTCL treatment: HyBryte(TM).
Via Investor Brand Network · October 9, 2025
In a groundbreaking collaboration, researchers from the Massachusetts Institute of Technology (MIT) and the Toyota Research Institute (TRI) have unveiled a revolutionary AI tool designed to create vast, realistic, and diverse virtual environments for robot training. This innovative system, dubbed "Steerable Scene Generation," promises to dramatically accelerate the development of more intelligent and adaptable robots, [...]
Via TokenRing AI · October 9, 2025
Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue
For long, treatment approaches to glioblastoma, the deadliest form of brain cancer, have assumed that the disease is localized. However, a recent study has found that GBM erodes the skulls of its victims and this could partially explain why the current therapies have had dismal success rates against the tumors.
Via Investor Brand Network · October 9, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients versus placebo, along with reduced neurofilament light chain (NFL), suggesting improved cellular health and potential disease-modifying effects. CEO Maria Maccechini said the findings confirm buntanetap’s multi-targeted mechanism and validate earlier preclinical and clinical results, advancing confidence in its potential to deliver meaningful therapeutic benefit.
Via Investor Brand Network · October 9, 2025
European stock markets are experiencing a remarkable surge, with key indices reaching unprecedented levels as of October 8, 2025. This robust performance is signaling a significant shift in investor sentiment towards the continent's equities, driven by a confluence of factors ranging from anticipated monetary easing by central banks to a
Via MarketMinute · October 8, 2025
Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently made public significant progress in its IzoView Breast CT system, a feature designed to give patients a customized radiation dose ideal for their composition and breast sizes ( ibn.fm/N83Cp ).
Via Investor Brand Network · October 8, 2025
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.
Via Investor Brand Network · October 8, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website.
Via Investor Brand Network · October 8, 2025
Denver, CO – October 7, 2025 – Solid Power, Inc. (NASDAQ: SLDP), a leading developer of all-solid-state battery technology, has reached a new 52-week high today, with its stock trading as high as $6.30 and closing at $6.33. This significant milestone underscores growing investor confidence in the company's groundbreaking advancements
Via MarketMinute · October 7, 2025
Munich, Germany – October 7, 2025 – Luxury automotive giant Bayerische Motoren Werke AG (BWM.DE) (BMWYY) has delivered a sobering outlook for the coming year, announcing a significant cut to its 2025 earnings forecast. The revised projections, revealed today, paint a picture of increased caution, primarily driven by a protracted slowdown
Via MarketMinute · October 7, 2025
Louisville, CO – October 7, 2025 – Solid Power (NASDAQ: SLDP), a leading developer of all-solid-state battery technology, has reached an impressive new 52-week high, with shares trading as high as $6.30 today. This significant surge in stock price reflects growing investor confidence and market optimism surrounding the company's continuous advancements
Via MarketMinute · October 7, 2025
The University of Waterloo has unveiled a groundbreaking AI-radar system poised to redefine remote health monitoring and early disease detection. This innovative, non-invasive technology tracks subtle changes in a patient's walk and other vital signs, offering an unprecedented "invisible safety net" for individuals, particularly in vulnerable populations and busy healthcare settings. By leveraging advanced radar [...]
Via TokenRing AI · October 7, 2025
Lund University Researchers Discover Why Leukemia Cells Evade the Immune System
While immunotherapy has scored a significant level of success in treating many types of cancer, it hasn’t registered similar efficacy in leukemia, especially acute myeloid leukemia, also known as AML. Researchers at Lund University, Sweden have found a possible reason why this could be so.
Via Investor Brand Network · October 7, 2025
October 6, 2025 - The global financial landscape is currently grappling with a significant shift as both the Euro and the Japanese Yen show signs of considerable weakening. While specific real-time events on this future date cannot be predicted, an analysis of ongoing economic trends and expert forecasts suggests that
Via MarketMinute · October 6, 2025
Clarksville, TN – October 4, 2025 – Microvast Holdings, Inc. (NASDAQ: MVST), a leading innovator in battery technology, has captured significant market attention by achieving a new 52-week high, reaching as high as $4.91, marking an impressive 1844.09% increase over the past year. This surge signals robust investor confidence and
Via MarketMinute · October 4, 2025
Shares of carbonate fuel cell technology developer FuelCell Energy (NASDAQ:FCEL)
jumped 16.3% in the afternoon session after the hydrogen fuel cell sector experienced a surge in positive sentiment after an analyst at H.C. Wainwright more than doubled the price target for industry peer Plug Power.
Via StockStory · October 3, 2025
Why Health Insurance Credits Led to the Federal Government Shutdown
Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits.
Via Investor Brand Network · October 3, 2025
The automotive industry is undergoing an unprecedented transformation, driven by the rapid global adoption of electric vehicles (EVs) and the relentless march towards fully autonomous driving. This profound shift has ignited an insatiable demand for highly specialized semiconductors, fundamentally repositioning the automotive sector as a primary growth engine for the chip industry. Vehicles are evolving [...]
Via TokenRing AI · October 4, 2025
Tesla (NASDAQ: TSLA) has once again captured headlines with its robust third-quarter 2025 delivery performance, reporting record global vehicle deliveries that comfortably surpassed analyst estimates. This surge was primarily driven by an aggressive pull-forward of demand in the United States, as consumers rushed to capitalize on the expiring federal EV
Via MarketMinute · October 2, 2025
On October 2nd, 2025, electric vehicle giant Tesla (NASDAQ: TSLA) announced an unprecedented third quarter for vehicle deliveries, significantly surpassing even the most optimistic projections from Wall Street. This remarkable achievement immediately triggered a substantial rally in Tesla's stock, sending shares to new 2025 highs and pushing the company's market
Via MarketMinute · October 2, 2025
Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm
In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S.
Via Investor Brand Network · October 2, 2025
The nascent DePIN (Decentralized Physical Infrastructure Networks) sector has a new focal point in PEAQ ($PEAQ), a Layer 1 blockchain that burst onto the scene with its Token Generation Event (TGE) in September 2024. Following an initial public sale on CoinList in May 2024 and subsequent listings on major exchanges around November 2024, PEAQ witnessed [...]
Via BreakingCrypto · October 1, 2025
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.
Via Investor Brand Network · October 1, 2025
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development
Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process ( https://ibn.fm/VIL67 ).
Via Investor Brand Network · October 1, 2025
Scorpion Venom Shows Promise in Brain Tumor Treatment
The sight of a scorpion moving towards you with its stinger raised can send a chill down the spine of the bravest among us. If you watched Fear Factor, you saw how terrified the contestants were to come face to face with these creatures. While scorpions have been portrayed as the stuff of nightmares, scientists have found that they can be useful in the fight against brain cancer .
Via Investor Brand Network · September 30, 2025